Measured Wealth Private Client Group LLC Invests $574,000 in Cencora, Inc. (NYSE:COR)

Measured Wealth Private Client Group LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 2,363 shares of the company’s stock, valued at approximately $574,000.

Other hedge funds have also made changes to their positions in the company. Rise Advisors LLC acquired a new stake in shares of Cencora during the first quarter worth $25,000. CVA Family Office LLC purchased a new position in shares of Cencora in the 1st quarter worth $34,000. Bruce G. Allen Investments LLC purchased a new position in shares of Cencora in the 1st quarter worth $43,000. Park Place Capital Corp purchased a new position in shares of Cencora in the 1st quarter worth $46,000. Finally, Trust Co. of Vermont purchased a new position in shares of Cencora in the 4th quarter worth $62,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Down 0.4 %

Shares of Cencora stock traded down $0.97 during trading hours on Tuesday, hitting $222.56. 1,455,291 shares of the company’s stock traded hands, compared to its average volume of 1,410,140. The stock has a 50 day simple moving average of $228.55 and a 200-day simple moving average of $228.47. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41. The company has a market cap of $44.39 billion, a PE ratio of 24.35, a PEG ratio of 1.57 and a beta of 0.45. Cencora, Inc. has a twelve month low of $171.65 and a twelve month high of $246.75.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating the consensus estimate of $3.65 by $0.15. The company had revenue of $68.41 billion during the quarter, compared to the consensus estimate of $70.60 billion. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The company’s revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm earned $3.50 earnings per share. Equities research analysts anticipate that Cencora, Inc. will post 13.44 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were paid a $0.51 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.92%. Cencora’s dividend payout ratio (DPR) is 22.32%.

Insider Buying and Selling

In related news, EVP Gina Clark sold 1,874 shares of Cencora stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $223.86, for a total value of $419,513.64. Following the completion of the transaction, the executive vice president now directly owns 13,284 shares in the company, valued at $2,973,756.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Cencora news, CEO Steven H. Collis sold 10,754 shares of Cencora stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at $67,702,698.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Gina Clark sold 1,874 shares of Cencora stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $223.86, for a total value of $419,513.64. Following the completion of the transaction, the executive vice president now owns 13,284 shares of the company’s stock, valued at $2,973,756.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,956,675 shares of company stock worth $422,352,056. Corporate insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. SVB Leerink reissued an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. Robert W. Baird raised their price objective on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Finally, Citigroup raised their price objective on Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $235.30.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.